Abstract:Objective: Cancer cells convert more glucose into lactate than healthy cells, what contributes to their growth advantage. Pyruvate kinase (PK) is a key rate limiting enzyme in this process, what makes it a promising potential therapeutic target. However, currently it is still unclear what consequences the inhibition of PK has on cellular processes. Here, we systematically investigate the consequences of PK depletion for gene expression, histone modifications and metabolism. Methods: Epigenetic, transcriptional and metabolic targets were analysed in different cellular and animal models with stable knockdown or knockout of PK. Results: Depleting PK activity reduces the glycolytic flux and causes accumulation of glucose-6-phosphate (G6P). Such metabolic perturbation results in stimulation of the activity of a heterodimeric pair of transcription factors MondoA and MLX but not in a major reprogramming of the global H3K9ac and H3K4me3 histone modification landscape. The MondoA:MLX heterodimer upregulates expression of thioredoxin-interacting protein (TXNIP) - a tumour suppressor with multifaceted anticancer activity. This effect of TXNIP upregulation extends beyond immortalised cancer cell lines and is applicable to multiple cellular and animal models. Conclusions: Our work shows that actions of often pro-tumorigenic PK and anti-tumorigenic TXNIP are tightly linked via a glycolytic intermediate. We suggest that PK depletion stimulates the activity of MondoA:MLX transcription factor heterodimers and subsequently, increases cellular TXNIP levels. TXNIP-mediated inhibition of thioredoxin (TXN) can reduce the ability of cells to scavenge reactive oxygen species (ROS) leading to the oxidative damage of cellular structures including DNA. These findings highlight an important regulatory axis affecting tumour suppression mechanisms and provide an attractive opportunity for combination cancer therapies targeting glycolytic activity and ROS-generating pathways.

Transketolase-Like Protein 1 (tktl1) is Required for Rapid Cell Growth and Full Viability of Human Tumor Cells

Hypoxia Induces the Expression of Transketolase-Like 1 in Human Colorectal Cancer

Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation

Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma.

RETRACTED: Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma (Retracted Article. See vol 10, pg 110, 2010)

Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer

Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation

Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo

The role of transketolase in human cancer progression and therapy

Transketolase Serves As a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma.

Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner

Gene Silencing of TKTL1 by RNAi Inhibits Cell Proliferation in Human Hepatoma Cells.

Transketolase counteracts oxidative stress to drive cancer development

Inhibition of Transketolase Improves the Prognosis of Colorectal Cancer

Research Progress of TKTL1 in Malignant Neoplasms

Effect of Transketolase-Like-1 on Proliferation of Human Colon Cancer Cell Line LoVo

Molecular Characteristics and Expression of TKTL1 in Germ Cells: Implications for Nontumour Cell Research

TKT maintains intestinal ATP production and inhibits apoptosis-induced colitis

Effect of Transketolase-Like Protein 1 on Proliferation of Human Nasopharyngeal Carcinoma Cells

TNKS1 Affects the Metabolism and Proliferation of Glioma via the PGC-1 Pathway

Depletion of pyruvate kinase (PK) activity causes glycolytic intermediate imbalances and reveals a PK-TXNIP regulatory axis